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Abstract
5-fluorouracil (5-FU) is a key chemotherapeutic agent in the treatment of many gastrointestinal
tract adenocarcinomas. Despite its proven therapeutic efficacy, 5-FU also possesses several
undesired cardiac toxicities, including coronary vasospasm, coronary thrombosis, cardiomyo-
pathy, and sudden cardiac death. This review addresses the incidence, mechanisms of action,
clinical presentation, risk stratification, and management of 5-FU associated cardiotoxicity; it
also highlights the importance of careful pre-administration cardiac risk stratification and
close monitoring during and after drug administration. (Cardiol J 2012; 19, 5: 453–458)
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Introduction
5-flourouracil (5-FU) has been a mainstay of the
chemotherapeutic treatment of gastrointestinal
malignancies for many years. Unfortunately, in ad-
dition to its beneficial antitumor effects, 5-FU also
possesses a number of important toxicities. Acute
coronary syndrome (ACS) precipitated by the ad-
ministration of 5-FU is a rare but well-established
phenomenon [1, 2] and only one of several adverse
cardiac effects related to this chemotherapeutic
agent. Additional cardiotoxic effects include cardio-
myopathy, vasospastic angina, coronary thrombo-
sis and dissection, malignant arrhythmias, and sud-
den cardiac death [3–7]. Furthermore, following any
cardiac complication, it is essential to weigh the
risks of repeat drug administration against the po-
tential for cure of the malignancy given this agent’s
proven efficacy. This review of the literature exa-
mines the cardiac complications of 5-FU and their
impact on therapeutic decision-making process,
taking into consideration epidemiology, mecha-
nisms of toxicity, clinical presentation, risk strati-
fication, treatment, and reintroduction of 5-FU.
5-FU is a fluoropyrimidine antimetabolite agent
key to several chemotherapy regimens, particular-
ly the treatment of gastrointestinal tract adenocar-
cinomas (Table 1). Combined with surgical resec-
tion, 5-FU therapy offers an impressive absolute
risk reduction of 5-year mortality of 5.8% in patients
with resectable gastric cancer [8]. Unfortunately,
like most chemotherapeutic agents, 5-FU also has
numerous toxic effects. The most common toxici-
ties associated with 5-FU include diarrhea, mucosi-
tis, myelosuppression, and thrombophlebitis of pe-
Table 1. Malignancies treated by 5-fluorouracil:
Labeled and unlabeled use.
Labeled use Unlabeled use
Colorectal Head and neck
Breast Esophageal
Pancreas Cervical
Stomach Renal
Bladder
Unknown primary
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ripheral veins [9]. The wide range of cardiotoxici-
ties related to 5-FU occur less frequently but are
typically more serious and include ventricular ar-
rhythmias, cardiomyopathy with significant left
ventricular systolic dysfunction, arterial vasospasm,
and direct endothelial toxicity, often culminating in
myocardial infarction (MI), heart failure (HF), and
cardiogenic shock [3–7] (Table 2). 5-FU cardio-
toxicity is, in fact, the second most common cause
of chemotherapy induced cardiotoxicity, second
only to anthracycline cardiotoxicity [10, 11].
Epidemiology
The reported incidence of cardiotoxicity relat-
ed to 5-FU ranges from 1.2% to 18% [1, 2, 12–14].
This wide variation is believed to be related to dose
dependency as well as the frequency of drug admi-
nistration. Tsibiribi et al. [15] evaluated 1350 patients
with no prior history of cardiac disease and analyzed
the number of cardiac complications. In their patient
population, 16 cases of cardiac complications (1.2%)
were noted. Cardiac complications reported in this
study included HF, MI and angina. A similar overall
incidence has been reported from other large pro-
spective studies with an overall range of 1.2% to 8%
[1, 2, 12, 13]. With shorter bolus regimens, the inci-
dence of cardiotoxicity typically lies between 1.6%
to 3% of cases [2]. With more prolonged regimens,
these percentages increase to 7.6% to 18% [14].
Recently, a review of 377 cases of 5-FU associated
cardiotoxicity confirmed that the majority of cases
of cardiotoxicity occur in the setting of continuous
infusion [6]. And while overall cardiac toxicity with
5-FU administration may vary, rates are uniformly
higher in patients with underlying heart disease, in-
cluding coronary artery disease (CAD), structural
heart disease, and cardiomyopathies [2, 16].
Mechanisms of toxicity
The precise etiology and pathophysiology of
5-FU cardiotoxicity is still unknown and based pri-
marily on limited animal studies, case reports, and
small clinical studies. Numerous mechanisms have
been proposed (Table 3). Clinically significant co-
ronary vasospasm causing myocardial ischemia is
the most commonly suspected mechanism, occur-
ring in 1.2–18% of cases, even in the absence of
CAD [1, 4, 17–19]. Both animal and human studies
demonstrate a dose dependent vasospasm that
ceases with cessation of drug administration [2, 4].
Experimental evidence also supports a direct toxic
effect of the 5-FU on the coronary endothelium [20]
and a hypercoagulable state which together preci-
pitate acute thrombotic events [3, 19].
Coronary vasospasm
The precise pathogenesis of 5-FU associated
cardiotoxicity has yet to be clearly elucidated. Co-
ronary vasospasm has historically been accepted
to be the main contributor to this clinical entity.
Ultrasound and angiographic studies demonstrate
both coronary artery and brachial artery vasospasm
following 5-FU infusion [21–23]. Prior case reports
reveal disease-free coronary arteries on angiogra-
phy [24]. Other studies note the efficacy of vasodi-
lator therapy, including nitrates and calcium chan-
nel blockers, in resolving chest pain and dynamic
ECG changes in the setting of 5-FU administra-
tion [24, 25]. 5-FU also has been shown in vitro to
induce vasoconstriction of vascular smooth mus-
cle cells via the activation of protein kinase C,
which resolves with administration of protein ki-
nase inhibitors [4]. Taken together, this data sup-
ports the theory of coronary artery vasospasm as
an important contributor to 5-FU induced cardio-
toxicity.
Endothelial dysfunction
Endothelial dysfunction and thrombus forma-
tion, independent of vasoconstriction, have also
been shown to serve as potential mechanisms of the
cardiotoxic effects of 5-FU administration. Several
animal studies examined the direct effects of 5-FU
on vascular endothelial cells and noted direct en-
Table 2. Cardiac toxicities reported with 5-fluoro-
uracil administration [3–7].
Angina Supraventricular tachycardia
Myocardial infarction Prolonged QT interval
Congestive heart failure Sudden death
Cardiomyopathy Cardiogenic shock
Myopericarditis Coronary dissection
Ventricular tachycardia
Table 3. Proposed mechanisms of 5-fluorouracil
induced cardiotoxicity [12, 14, 16, 34, 35, 39, 41].
Coronary artery spasm
Autoimmune-mediated injury of the myocardium
Endothelial damage
Thrombogenic effects or thrombus formation
Direct myocardial toxicity causing necrosis
Global dysfunction
Accumulation of metabolites
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dothelial damage and platelet and fibrin accumula-
tion with increased thrombus formation on both
gross examination and electron microscopic evalu-
ation [20, 26]. With exposure to 5-FU, damage to
endothelial cells followed by platelet accumulation
and fibrin formation was observed [26].
Kuzel et al. [27] demonstrated an increase in
the quantity of fibrinopeptide A and a decrease in
the amount of protein C activity in the presence of
5-FU, which together make a blood vessel more
susceptible to thrombus formation. Another study
comparing the adverse effects of 5-FU and metho-
trexate on arterial endothelial cells showed an in-
creased incidence of endothelial injury and subse-
quent thrombosis with 5-FU administration [28].
Direct myocardial injury
Direct myocardial injury has also been suggest-
ed to play a role in 5-FU induced cardiotoxicity. De
Forni et al. [12] suggested the possibility of a di-
rect drug (or drug-metabolite) toxic action on the
myocardium, particularly given evidence that there
is global systolic dysfunction, which does not cor-
respond to any individual coronary artery territo-
ry. Another animal study demonstrated different
toxic effects depending on the dose and frequency
of drug administration [29]. A single large dose de-
monstrated massive hemorrhagic MI associated
with coronary spasm, while repeated lower dose in-
fusions resulted in left ventricular hypertrophy with
necrosis, thickening of arteries, and apoptosis of
endothelial cells. This same study also demonstrat-
ed that 5-FU can cause a diffuse myocarditis instead
of vasospasm with subendocardial sparing along
with inflammation [29]. Another case report utiliz-
ing ventricular biopsy demonstrated sarcoplasmic
reticulum dilatation, similar to doxorubicin-asso-
ciated cardiomyopathy [30].
Accumulation of toxic metabolites
The generation of metabolites of 5-FU is also
likely to serve as another important mediator of this
drug’s cardiotoxicity of this drug. One such down-
stream metabolite is alpha-fluoro-beta-alanine
(FBAL). Muneoka et al. [31] showed both elevated
levels of FBAL after 5-FU induced MI as well as
the absence of ischemia with subsequent treatment
with a derivative of 5-FU which does not metabo-
lize to FBAL.
Other mechanisms
Several other unique mechanisms of cardio-
toxicity have been proposed. A study analyzing
erythyrocyte membranes suggested 5-FU induced
changes to erythyrocyte membranes causing in-
creased fluidity and conversion to echinocytic
shapes. The membrane structural alterations
caused functional changes diminished the erythro-
cyte’s ability to deliver and transport oxygen, lead-
ing in turn to ischemia and myocardial injury [32].
Another study by Karabay et al. [33]  suggested
a Kounis syndrome as a potential toxic etiology,
with a 5-FU induced allergic insult causing coronary
vasospasm, which was partially responsive to anti-
histamine therapy. Kounis syndrome can be vaso-
spastic or nonvasospastic, and is caused by an aller-
gic insult causing a release of inflammatory media-
tors that can rupture coronary artery plaques. It
typically responds to glucocorticoids and antihista-
mines, along with vasodilators such as nitrites and
calcium channel blockers — however, given the fact
that it can be either vasospastic or not, varying
results with medications (such as verapamil) are
experienced.
Clinical presentation
One of the earliest papers describing 5-FU car-
diotoxicity illustrated that patients with cardio-
toxicity secondary to 5-FU administration present
with chest pain, ST and T wave ECG changes, and
supraventricular and ventricular arrhythmias [34].
Other authors have noted chest pain with dynamic
ECG changes as well as ST elevation MI [12, 35].
Finally, regional left ventricular wall motion abnor-
malities and global systolic dysfunction have also
been observed [12].
Cardiotoxicity with 5-FU infusions tends occur
most commonly during the first cycle of administra-
tion [35]. The median time to symptoms is 12 h fol-
lowing initiation of the infusion with a range between
3 h and 18 h [17], although in animal studies median
times to symptom-onset have been more variable
and have been noted to occur as late as 48 h into an
infusion [28]. Another study also suggests earlier
onset and increased severity of symptoms with high-
er dose regimens or repeat drug administration [36].
Angina
Angina has been shown to be one of the most
common cardiac symptoms associated with 5-FU
administration [14]. Up to 19% of the patients in
a series of patients by Wacker et al. [37] experienced
angina during treatment, with episodes lasting up to
12 h after cessation of drug infusion. In the most
striking case series, nearly 90% of patients experi-
enced angina, often with troponin release or diagnos-
tic ECG changes following 5-FU infusion [17].
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Silent ischemia and myocardial infarction
Isolated ST changes without anginal symptoms
have also been commonly observed on continuous
ambulatory ECG monitoring in patients receiving
5-FU therapy. A study by Rezkalla et al. [16] de-
monstrated ischemic and arrhythmic ECG changes,
to include ST-segment deviation and QT-prolonga-
tion, in nearly 68% of patients receiving infusions
of 5-FU. Others have noted incidences of asymp-
tomatic diagnostic ECG changes in up to 88% of
patients during 5-FU infusion, with nearly 7% dem-
onstrating elevated cardiac enzymes [12, 35]. An-
other retrospective examination of 377 case reports
revealed acute MI in 22% of patients during 5-FU
administration [6], while a prospective study of
26 patients suggested infarction by ECG and symp-
tom criteria in nearly 35% of patients receiving
5-FU [1]. Coronary artery dissection causing an
ACS has also been described with vasospasm-
-induced disruption of the endothelium cited as
a possible mechanism of action [38].
Arrhythmia
Transient, asymptomatic bradycardia has been
also been reported with 5-FU infusion. In a study
by Talapatra et al. [39], 6 patients experienced
bradycardia following treatment with continuous
5-FU infusion. Significant prolongation of QTc in-
tervals and frequent ventricular arrhythmias have
also been found on Holter monitoring associated
with 5-FU infusion [37]. A review of 22 patients
demonstrated significant early prolongations of the
QT interval which persisted throughout the dura-
tion of chemotherapy [40] and another case series
described QT prolongation with torsade de pointes
in a patient receiving 5-FU infusions [5].
Myocarditis and heart failure
Myocarditis and HF are other manifestations
of 5-FU cardiotoxicity. One case report described
acute toxic myocarditis following a short infusion
of 5-FU [41]. Subsequent coronary angiography
demonstrated normal coronary arteries without
evidence of coronary vasospasm. On left ventricu-
logram, global hypokinesis with an ejection fraction
of 25% was noted. The patient was treated medi-
cally and left ventricular systolic function ultimately
normalized. An additional case demonstrated glo-
bal systolic dysfunction with 5-FU infusion and
evidence of global myocarditis on diagnostic evalu-
ation [42]. In a prospective study by Jensen et al. [43]
significant NT-proBNP levels were noted in pa-
tients following 5-FU administration. In another
case series, 3.5% of patients presented with acute
decompensated HF during their first course of che-
motherapy [13].
Risk stratification
Risk factors for cardiotoxicity with 5-FU include
preexisting CAD or HF, impaired renal clearance,
prior symptoms with 5-FU administration, and long-
er infusion regimens [3, 14]. Other predisposing fac-
tors for cardiotoxicity include prior chest irradiation
and treatment with other chemotherapeutic agents
with cardiac side effects [44]. Overall, patients with
underlying CAD demonstrate rates of cardiotoxicity
in the 5–15% range [14, 45]. In addition to increasing
the frequency of cardiotoxicity, the presence of pre-
existing heart disease increases the severity of car-
diotoxic reactions to 5-FU [3]. Accordingly, a careful
pre-administration cardiac evaluation is essential [46].
Despite the increased incidence of cardio-
toxicity in patients with preexisting heart disease,
the majority of cases occur in patients without any
prior identified cardiac history and it is often diffi-
cult to predict which individual patient will be si-
gnificantly adversely affected by the drug [12, 35].
Thus, in conjunction with a thorough pre-treatment
clinical assessment, frequent symptom, blood pres-
sure, and ECG monitoring are essential components
of any treatment protocol [46].
Treatment and prophylaxis
Following the recognition of acute cardio-
toxicity, drug therapy should be ceased immediate-
ly, and treatment with nitrates or calcium channel
blockers initiated (Table 4) [47]. In some studies,
up to 70–90% of patients respond to such conser-
vative therapy [6, 35]. Others report response rates
to these drugs of less than 50% [3, 48].
Various preventive strategies have been pur-
sued as well. Several studies have utilized oral
capecitabine, an oral pro-drug of 5-FU, as an alter-
native agent to mitigate the adverse effects of
5-FU. Unfortunately, several reports still demon-
strate drug-induced cardiotoxicity, albeit delayed
until significant metabolite accumulation occurred
[1, 25]. Eskilsson et al. [48] attempted to prevent
vasospasm-induced 5-FU cardiotoxicity via pread-
ministration of verapamil without significant clini-
cal effect. Another study by Salepci et al. [49] pur-
sued prophylactic administration of ACE inhibitors
for the prevention of 5-FU induced cardiomyopathy
without effect. Another potentially promising pre-
ventive therapy is the pre-administration of a strong
antioxidant like probucol, which has demonstrated
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effectiveness in the lab, but whose efficacy has yet
to be confirmed in human subjects [19]. Overall,
most investigators suggest decrease in drug dos-
age as the most effective strategy [6, 48].
Reintroduction of 5-FU
Reintroducing 5-FU to patients with a history
of cardiotoxicity following prior 5-FU administra-
tion is not currently advised. Repeated exposure to
5-FU after documented cardiotoxicity carries a re-
currence rate of 82–100% [17]. Moreover, a review
of reexposure of 5-FU after cardiotoxicity revealed
a death rate of 18% in patients who were reexposed
to the drug [6]. A series by Clavel et al. [50] revealed
that readministration of 5-FU in a 28 patient cohort
caused myocardial necrosis in 4 cases, and fatal
cardiogenic shock in another 4 cases. If after care-
ful consideration of the risks and benefits, rechal-
lenge with 5-FU is deemed clinically appropriate,
a reduction of dosage may be a viable option [51].
A prolonged course of pretreatment with nitrates and
calcium channel blockers, continued during the drug
infusion, has also been suggested [1]. Additionally,
there is some evidence that in patients who develop
cardiotoxicity to 5-FU, administration of another
chemotherapy such as raltitrexed is an option [52].
Raltitrexed is a thymidylate synthase inhibitor that
thus far does not show the cardiotoxic profile that
5-FU seems to have, and may be an alternative in high
risk patients [53]. Regardless, close monitoring in
an inpatient setting is mandated for patients under-
going rechallenge with 5-FU following cardiotoxici-
ty (Table 4). In our case, the patient ultimately re-
sumed 5-FU therapy under close monitoring in an
effort to achieve complete cure of his malignancy and
experienced no further treatment complications.
Conclusions
With increased usage of 5-FU for the treatment
of gastrointestinal malignancies, cardiotoxicities
may be expected to be encountered more frequently
in the future. A pre-chemotherapy history and
physical is paramount and all patients should have
a careful evaluation for cardiovascular risk factors
as well as any subclinical CAD or cardiomyopathies
which may be exacerbated by 5-FU infusion. Al-
though asymptomatic ECG changes, mild angina,
and stable supraventricular arrhythmias predomi-
nate, dangerous complications such as MI, ventri-
cular arrhythmias, decompensated HF, and death
may also result from 5-FU administration. The etio-
logy of 5-FU induced cardiotoxicity is probably mul-
tifactorial and may include coronary vasospasm,
direct endothelial and myocardial injury, and accu-
mulation of toxic metabolites. Pre-treatment with
nitrates or calcium channel blockers may help to
reduce the incidence of toxic effects although to
date the only demonstrated effective strategies in-
volve dose decreases or cessation of therapy. For
those patients undergoing drug readministration
following cardiotoxicity, therapy should take place
in a carefully monitored setting. Overall, success-
ful administration of 5-FU based therapies should
involve a multidisciplinary approach to maximize
clinical benefit and reduce potential harm.
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